Tirzepatide’s cardiovascular effects in clinical practice

Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.

By
Kathryn Wighton
August 28, 2026
4 min

MDSpire News

Overview

Tirzepatide is associated with a lower 1-year risk of major adverse cardiovascular events compared to sitagliptin in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The study utilized a population-based cohort design analyzing administrative claims data.

Background

Understanding the cardiovascular effects of diabetes medications is crucial as patients with type 2 diabetes often have an increased risk of cardiovascular events. This study provides insights into the comparative effectiveness of tirzepatide against sitagliptin, a commonly used medication in this population.

Data Highlights

Outcome	Tirzepatide	Sitagliptin
Weighted MACE Risk	3%	4%
Myocardial Infarction or Stroke Risk	2%	3%

Key Findings

Tirzepatide was associated with a lower risk of major adverse cardiovascular events (MACE) compared to sitagliptin.
The estimated number needed to treat with tirzepatide to prevent one MACE event was 70.
The risk of ischemic stroke was similar between tirzepatide and sitagliptin.
Tirzepatide was linked to fewer infection-related hospital admissions compared to sitagliptin.
Gastrointestinal adverse events did not differ significantly between the two groups.

Clinical Implications

Clinicians may consider tirzepatide as a treatment option for patients with type 2 diabetes and established cardiovascular disease, given its lower associated risk of MACE. However, caution is advised regarding potential residual confounding in mortality findings.

Conclusion

The findings indicate that further investigation is warranted regarding the cardiovascular effects of tirzepatide compared to sitagliptin in patients with type 2 diabetes and established cardiovascular disease.